2 completed, 2 recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Cutaneous Neurofibroma: new trials by email Literature Review of Cutaneous Neurofibroma trials Research Report on Cutaneous Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | Johns Hopkins University | 10 | 2026-02-01 | 2026-05-08 |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). Mirdametinib - NF1, Cutaneous Neurofibroma | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2024-02-12 | 2026-04-13 |
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 DPCP - Cutaneous Neurofibroma | Phase 1 | Completed | Nicholas Gulati | 17 | 2022-09-14 | 2024-05-06 |
| Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas Kybella, 1064nm laser, 755nm Alexandrite Laser - Cutaneous Neurofibroma | Phase 1 | Completed | Massachusetts General Hospital | 34 | 2021-06-02 | 2025-02-21 |
Neurofibromatosis 1 (3) · Neurofibromatoses (2) · Neurofibroma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Nerve Tissue (3) · Neoplastic Syndromes, Hereditary (3) · Nerve Sheath Neoplasms (3) · Nervous System Diseases (3) · Neurocutaneous Syndromes (3) · Neurodegenerative Diseases (3) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3) · Neurofibroma (2) · Nervous System Neoplasms (1)
Deoxycholic Acid (1) · Lasers (1) · Lasers, Solid-State (1) · diphenylcyclopropenone (1) · mirdametinib (1) · talimogene laherparepvec (1)
Johns Hopkins University (2) · Massachusetts General Hospital (1) · Nicholas Gulati (1)
United States (4)
Carlos Romo, MD (2) · Nicholas Gulati, MD, PhD (1) · R. Rox Anderson, MD (1) · Rebecca Brown, MD, PhD (1)